RSV Infection Prophylaxis Guidelines

Palivizumab (Synagis®) for RSV prevention

IWK Health manages the utilization of palivizumab in Nova Scotia for the prevention of respiratory syncytial virus (RSV) infection in infants. For information regarding the guidelines for the use of this product and the request approval process, please go to the palivizumab section of the IWK Health website or contact:

Karen Chestney, RN
Provincial Palivizumab Monitoring Nurse
IWK Health
(902) 470-2723

Date Revised: 
September, 2021